This passive promotion of methylation’ strategy is an important paradigm in targeted epigenetic therapy, and demonstrates particular breakthrough potential in PAX3-FOXO1 fusion-positive rhabdomyosarcoma. This evidence concerns the gene PAX3 and rhabdomyosarcoma.